Tekmira Pharmaceuticals Corporation (TKMR), which hit a fresh intraday high of $26.05 – received a mention at Maxim Group this morning. The firm said it believes Tekmira’s FDA TKM-Ebola drug downgrade to a partial ‘hold’ from a full clinical ‘hold’, an action enabling the potential use of TKM-Ebola in individuals that are already infected with Ebola virus, will highlight the depth and scope of the Biodefense industry and how companies like Tekmira Pharma might benefit.
Last week analysts at Maxim Group issued a research note to investors where they reiterated their ‘Buy’ rating and $23.00 price target on the shares of Tekmira.
TKMR, which surged more than 15% in trading Monday, a move that follows a 45% spike on Friday, is trading at an unusually high volume with more than 14.5 million shares changing hands at $23.48 as of 11:11 am ET. Ticker is currently at 14x its average 3 month average volume of 1.05 million shares and printing a whopping one year return of about 317% and a year-to-date return of around 191%. TKMR spiked more than 74% last week.
In the past 52 weeks, shares of Tekmira Pharmaceuticals have traded between a low of $5.08 and a high of $31.48.
The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.